Advertisement
U.S. markets closed

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3000+0.0100 (+0.78%)
At close: 04:00PM EDT
1.3100 +0.01 (+0.77%)
After hours: 05:48PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.2900
Open1.3300
Bid1.2700 x 700
Ask1.3200 x 300
Day's Range1.2800 - 1.4100
52 Week Range0.5300 - 1.5900
Volume2,778,684
Avg. Volume2,033,181
Market Cap226.021M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.5700
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 09, 2012
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VXRT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaxart, Inc. - Common Stock
    Technical Assessment: Neutral in the Intermediate-TermWas that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.
    Rating
    Fair Value
    Economic Moat
    11 hours agoArgus Research
View more
  • GlobeNewswire

    Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

    SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccinationSpeaker: Dr. Sean

  • GlobeNewswire

    Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo, effective March 18, 2024. The awards were made pursuant to the Company’s previously disclosed offer letter with Mr. Lo, and as a material inducement to his joining the Company as President and Chief Execu

  • Simply Wall St.

    Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)

    Key Insights Using the 2 Stage Free Cash Flow to Equity, Vaxart fair value estimate is US$0.90 With US$1.08 share...